https://www.321223.comnone 2026-11-11 07:29:45 daily 0.8 https://www.321223.com/xwdt/xydt/ 2026-11-11 07:29:25 daily 0.8 https://www.321223.com/xwdt/xjz/ 2026-11-11 07:29:05 daily 0.8 https://www.321223.com/xwdt/html/990.html 2026-11-11 07:28:45 daily 0.8 https://www.321223.com/xwdt/html/979.html 2026-11-11 07:28:25 daily 0.8 https://www.321223.com/xwdt/html/967.html 2026-11-11 07:28:05 daily 0.8 https://www.321223.com/xwdt/html/943.html 2026-11-11 07:27:45 daily 0.8 https://www.321223.com/xwdt/html/927.html 2026-11-11 07:27:25 daily 0.8 https://www.321223.com/xwdt/html/907.html 2026-11-11 07:27:05 daily 0.8 https://www.321223.com/xwdt/html/900.html 2026-11-11 07:26:45 daily 0.8 https://www.321223.com/xwdt/html/897.html 2026-11-11 07:26:25 daily 0.8 https://www.321223.com/xwdt/html/729.html 2026-11-11 07:26:05 daily 0.8 https://www.321223.com/xwdt/html/656.html 2026-11-11 07:25:45 daily 0.8 https://www.321223.com/xwdt/html/592.html 2026-11-11 07:25:25 daily 0.8 https://www.321223.com/xwdt/html/575.html 2026-11-11 07:25:05 daily 0.8 https://www.321223.com/xwdt/html/557.html 2026-11-11 07:24:45 daily 0.8 https://www.321223.com/xwdt/html/488.html 2026-11-11 07:24:25 daily 0.8 https://www.321223.com/xwdt/html/465.html 2026-11-11 07:24:05 daily 0.8 https://www.321223.com/xwdt/html/419.html 2026-11-11 07:23:45 daily 0.8 https://www.321223.com/xwdt/html/348.html 2026-11-11 07:23:25 daily 0.8 https://www.321223.com/xwdt/html/314.html 2026-11-11 07:23:05 daily 0.8 https://www.321223.com/xwdt/html/270.html 2026-11-11 07:22:45 daily 0.8 https://www.321223.com/xwdt/html/233.html 2026-11-11 07:22:25 daily 0.8 https://www.321223.com/xwdt/html/1310.html 2026-11-11 07:22:05 daily 0.8 https://www.321223.com/xwdt/html/1304.html 2026-11-11 07:21:45 daily 0.8 https://www.321223.com/xwdt/html/1303.html 2026-11-11 07:21:25 daily 0.8 https://www.321223.com/xwdt/html/1302.html 2026-11-11 07:21:05 daily 0.8 https://www.321223.com/xwdt/html/1301.html 2026-11-11 07:20:45 daily 0.8 https://www.321223.com/xwdt/html/1300.html 2026-11-11 07:20:25 daily 0.8 https://www.321223.com/xwdt/html/1297.html 2026-11-11 07:20:05 daily 0.8 https://www.321223.com/xwdt/html/1296.html 2026-11-11 07:19:45 daily 0.8 https://www.321223.com/xwdt/html/1295.html 2026-11-11 07:19:25 daily 0.8 https://www.321223.com/xwdt/html/1294.html 2026-11-11 07:19:05 daily 0.8 https://www.321223.com/xwdt/html/1286.html 2026-11-11 07:18:45 daily 0.8 https://www.321223.com/xwdt/html/1275.html 2026-11-11 07:18:25 daily 0.8 https://www.321223.com/xwdt/html/1274.html 2026-11-11 07:18:05 daily 0.8 https://www.321223.com/xwdt/html/1273.html 2026-11-11 07:17:45 daily 0.8 https://www.321223.com/xwdt/html/1272.html 2026-11-11 07:17:25 daily 0.8 https://www.321223.com/xwdt/html/1271.html 2026-11-11 07:17:05 daily 0.8 https://www.321223.com/xwdt/html/1270.html 2026-11-11 07:16:45 daily 0.8 https://www.321223.com/xwdt/html/1259.html 2026-11-11 07:16:25 daily 0.8 https://www.321223.com/xwdt/html/1258.html 2026-11-11 07:16:05 daily 0.8 https://www.321223.com/xwdt/html/1257.html 2026-11-11 07:15:45 daily 0.8 https://www.321223.com/xwdt/html/1256.html 2026-11-11 07:15:25 daily 0.8 https://www.321223.com/xwdt/html/1255.html 2026-11-11 07:15:05 daily 0.8 https://www.321223.com/xwdt/html/1254.html 2026-11-11 07:14:45 daily 0.8 https://www.321223.com/xwdt/html/1253.html 2026-11-11 07:14:25 daily 0.8 https://www.321223.com/xwdt/html/1251.html 2026-11-11 07:14:05 daily 0.8 https://www.321223.com/xwdt/html/1250.html 2026-11-11 07:13:45 daily 0.8 https://www.321223.com/xwdt/html/1249.html 2026-11-11 07:13:25 daily 0.8 https://www.321223.com/xwdt/html/1248.html 2026-11-11 07:13:05 daily 0.8 https://www.321223.com/xwdt/html/1247.html 2026-11-11 07:12:45 daily 0.8 https://www.321223.com/xwdt/html/1246.html 2026-11-11 07:12:25 daily 0.8 https://www.321223.com/xwdt/html/1245.html 2026-11-11 07:12:05 daily 0.8 https://www.321223.com/xwdt/html/1241.html 2026-11-11 07:11:45 daily 0.8 https://www.321223.com/xwdt/html/1240.html 2026-11-11 07:11:25 daily 0.8 https://www.321223.com/xwdt/html/1235.html 2026-11-11 07:11:05 daily 0.8 https://www.321223.com/xwdt/html/1234.html 2026-11-11 07:10:45 daily 0.8 https://www.321223.com/xwdt/html/1226.html 2026-11-11 07:10:25 daily 0.8 https://www.321223.com/xwdt/html/1225.html 2026-11-11 07:10:05 daily 0.8 https://www.321223.com/xwdt/html/1224.html 2026-11-11 07:09:45 daily 0.8 https://www.321223.com/xwdt/html/1200.html 2026-11-11 07:09:25 daily 0.8 https://www.321223.com/xwdt/html/1199.html 2026-11-11 07:09:05 daily 0.8 https://www.321223.com/xwdt/gsxw/ 2026-11-11 07:08:45 daily 0.8 https://www.321223.com/media/zyupr30a/hkex-eps_20260930_12354321_0.pdf 2026-11-11 07:08:25 daily 0.8 https://www.321223.com/media/znwhl4oq/final-2025-esmo-ct041-poster.pdf 2026-11-11 07:08:05 daily 0.8 https://www.321223.com/media/xvghsvht/2022-interim-report.pdf 2026-11-11 07:07:45 daily 0.8 https://www.321223.com/media/xmlelc50/poster_abstract-2557.pdf 2026-11-11 07:07:25 daily 0.8 https://www.321223.com/media/wsnbvqta/通用型car-t产品ct0596及ct1190b的积极临床数据.pdf 2026-11-11 07:07:05 daily 0.8 https://www.321223.com/media/wsnbvqta/ͨ����car-t��Ʒct0596��ct1190b�Ļ����ٴ�����.pdf 2026-11-11 07:06:45 daily 0.8 https://www.321223.com/media/wncfkrfb/公示件-泽沃基奥仑赛注射液使用培训和认证的医疗机构名单汇总-0720.pdf 2026-11-11 07:06:25 daily 0.8 https://www.321223.com/media/wivjdipc/2023-hy.pdf 2026-11-11 07:06:05 daily 0.8 https://www.321223.com/media/wccjzwma/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b.pdf 2026-11-11 07:05:45 daily 0.8 https://www.321223.com/media/vujmc2eu/green-application-form.pdf 2026-11-11 07:05:25 daily 0.8 https://www.321223.com/media/vtudbnl4/final-2025-asco-oral-presentation.pdf 2026-11-11 07:05:05 daily 0.8 https://www.321223.com/media/vtoc44bj/en_hkex-eps_20240909_11360644_0.pdf 2026-11-11 07:04:45 daily 0.8 https://www.321223.com/media/vbnbibn2/general_terms_and_conditions_of_purchase_carsgen_us_final_20231110.pdf 2026-11-11 07:04:25 daily 0.8 https://www.321223.com/media/ub5lsa0p/car-tcr-summit-2022-final.pdf 2026-11-11 07:04:05 daily 0.8 https://www.321223.com/media/u1wdz4jn/hkex-eps_20241210_11472656_0.pdf 2026-11-11 07:03:45 daily 0.8 https://www.321223.com/media/tz2paqen/global-offering-2-cn.pdf 2026-11-11 07:03:25 daily 0.8 https://www.321223.com/media/txzffkap/hkex-eps_20221209_10538157_0fan.pdf 2026-11-11 07:03:05 daily 0.8 https://www.321223.com/media/tu3jixci/hkex-eps_20230419_10692749_0_en.pdf 2026-11-11 07:02:45 daily 0.8 https://www.321223.com/media/t5zguoik/hkex-eps_20260930_12354322_0.pdf 2026-11-11 07:02:25 daily 0.8 https://www.321223.com/media/t5knxqvb/1751.pdf 2026-11-11 07:02:05 daily 0.8 https://www.321223.com/media/syrk40jm/final-carsgen-therapeutics-corporate-deck_oct-28.pdf 2026-11-11 07:01:45 daily 0.8 https://www.321223.com/media/suzbnpln/eha-2025-ct071-pf1164_juan-du.pdf 2026-11-11 07:01:25 daily 0.8 https://www.321223.com/media/stwjmue4/final-�Ƽ�ҩҵ��˾����-oct-13.pdf 2026-11-11 07:01:05 daily 0.8 https://www.321223.com/media/stwjmue4/final-Z6尊龙凯时药业公司介绍-oct-13.pdf 2026-11-11 07:00:45 daily 0.8 https://www.321223.com/media/rzmju0v4/ct0596-eha2026-poster-final-1.pdf 2026-11-11 07:00:25 daily 0.8 https://www.321223.com/media/rqfnslii/2024041800870_c.pdf 2026-11-11 07:00:05 daily 0.8 https://www.321223.com/media/pudgixhi/aacr-cldn18-2-poster.pdf 2026-11-11 06:59:45 daily 0.8 https://www.321223.com/media/pp2bzlw0/�Ƽ�ҩҵ2025Ͷ���߿�����.pdf 2026-11-11 06:59:25 daily 0.8 https://www.321223.com/media/pp2bzlw0/Z6尊龙凯时药业2025投资者盛开日.pdf 2026-11-11 06:59:05 daily 0.8 https://www.321223.com/media/pmglacuc/2023-hy-e.pdf 2026-11-11 06:58:45 daily 0.8 https://www.321223.com/media/pjrcksuy/global-offering.pdf 2026-11-11 06:58:25 daily 0.8 https://www.321223.com/media/oy2arfcg/poster-1056p.pdf 2026-11-11 06:58:05 daily 0.8 https://www.321223.com/media/otzepuxu/contractual-arrangements-which-are-material-contracts.pdf 2026-11-11 06:57:45 daily 0.8 https://www.321223.com/media/o3nbxckn/2022-ash.pdf 2026-11-11 06:57:25 daily 0.8 https://www.321223.com/media/o2hhwg5j/procedures-for-shareholders-to-propose-directors-en.pdf 2026-11-11 06:57:05 daily 0.8 https://www.321223.com/media/nfkjdysh/e_ham25051660ann-20250904-20250904_1323.pdf 2026-11-11 06:56:45 daily 0.8 https://www.321223.com/media/n2ih2b4l/carsgen-therapeutics-2025-investor-day.pdf 2026-11-11 06:56:25 daily 0.8 https://www.321223.com/media/mi3ppjp2/final-�Ƽ�ҩҵ��˾����-oct-28.pdf 2026-11-11 06:56:05 daily 0.8 https://www.321223.com/media/mi3ppjp2/final-Z6尊龙凯时药业公司介绍-oct-28.pdf 2026-11-11 06:55:45 daily 0.8 https://www.321223.com/media/mckjltow/2025-interim-report.pdf 2026-11-11 06:55:25 daily 0.8 https://www.321223.com/media/mbijtrcb/final-�Ƽ�ҩҵ��˾����-sept-1.pdf 2026-11-11 06:55:05 daily 0.8 https://www.321223.com/media/mbijtrcb/final-Z6尊龙凯时药业公司介绍-sept-1.pdf 2026-11-11 06:54:45 daily 0.8 https://www.321223.com/media/malcgk31/green-application-form-cn.pdf 2026-11-11 06:54:25 daily 0.8 https://www.321223.com/media/lzxm1ezb/4845_ash-poster.pdf 2026-11-11 06:54:05 daily 0.8 https://www.321223.com/media/lwmjqyw3/2821.pdf 2026-11-11 06:53:45 daily 0.8 https://www.321223.com/media/llznor0x/2023-asco-gi-poster_ab011-mono-combo-_0106final.pdf 2026-11-11 06:53:25 daily 0.8 https://www.321223.com/media/lgei54pn/global-offering-2.pdf 2026-11-11 06:53:05 daily 0.8 https://www.321223.com/media/kv3nfwei/2021-annual-report-en.pdf 2026-11-11 06:52:45 daily 0.8 https://www.321223.com/media/kuxd30iu/final-carsgen-therapeutics-corporate-deck_sept-1.pdf 2026-11-11 06:52:25 daily 0.8 https://www.321223.com/media/kolhjqpf/2022-interim-report-cn.pdf 2026-11-11 06:52:05 daily 0.8 https://www.321223.com/media/jyyh33c4/2021-esmo-ct041-oral-presentation.pdf 2026-11-11 06:51:45 daily 0.8 https://www.321223.com/media/jyvpmslq/hkex-eps_20260915_12332734_0.pdf 2026-11-11 06:51:25 daily 0.8 https://www.321223.com/media/iznib0sv/c_ham25051660ann-20250904-20250904_1325.pdf 2026-11-11 06:51:05 daily 0.8 https://www.321223.com/media/i4bdwekv/carsgen_arrangements-of-electronic-dissemination-of-corporate-communications_en.pdf 2026-11-11 06:50:45 daily 0.8 https://www.321223.com/media/hn1pbu44/2022_asco_annual_meeting_poster_14may2022.pdf 2026-11-11 06:50:25 daily 0.8 https://www.321223.com/media/hiuks2qn/ct041-cg4006-asco-2024_v3-0_20240603-1.pdf 2026-11-11 06:50:05 daily 0.8 https://www.321223.com/media/hgpk5qic/hkex-eps_20241210_11472655_0.pdf 2026-11-11 06:49:45 daily 0.8 https://www.321223.com/media/ghcj2aj4/cn_hkex-eps_20240909_11360645_0.pdf 2026-11-11 06:49:25 daily 0.8 https://www.321223.com/media/gdon4wmr/ct0596-ash-poster-20251110-for-submision.pdf 2026-11-11 06:49:05 daily 0.8 https://www.321223.com/media/g4aoe02d/公示文件-舒瑞基奥仑赛注射液使用培训和认证的医疗机构名单-0720.pdf 2026-11-11 06:48:45 daily 0.8 https://www.321223.com/media/fdyfi4ug/carsgen_arrangements-of-electronic-dissemination-of-corporate-communications_cn.pdf 2026-11-11 06:48:25 daily 0.8 https://www.321223.com/media/f5pblhde/ct053-ash-poster_-4762.pdf 2026-11-11 06:48:05 daily 0.8 https://www.321223.com/media/f1jny5l1/sitc-2023-poster.pdf 2026-11-11 06:47:45 daily 0.8 https://www.321223.com/media/eb0lckhd/2021-esmo-ct041-口头汇报.pdf 2026-11-11 06:47:25 daily 0.8 https://www.321223.com/media/eatjktro/hkex-eps_20260410_12102280_0.pdf 2026-11-11 06:47:05 daily 0.8 https://www.321223.com/media/dxnj3spj/ct0590-ash-poster_-4843.pdf 2026-11-11 06:46:45 daily 0.8 https://www.321223.com/media/djkf4urr/hkex-eps_20221209_10538156_0en.pdf 2026-11-11 06:46:25 daily 0.8 https://www.321223.com/media/caaamxan/hkex-eps_20260522_12169562_0.pdf 2026-11-11 06:46:05 daily 0.8 https://www.321223.com/media/brtijrlk/2021-annual-report.pdf 2026-11-11 06:45:45 daily 0.8 https://www.321223.com/media/brqhxcy4/2024041800869.pdf 2026-11-11 06:45:25 daily 0.8 https://www.321223.com/media/agmjug4b/final-eha2024-ppt-v2_clean_06.pdf 2026-11-11 06:45:05 daily 0.8 https://www.321223.com/media/5yod15ea/abstract-4095_ct0180_poster.pdf 2026-11-11 06:44:45 daily 0.8 https://www.321223.com/media/5owm5t4b/global-offering-cn.pdf 2026-11-11 06:44:25 daily 0.8 https://www.321223.com/media/5drbms3p/2024-annual-report-c.pdf 2026-11-11 06:44:05 daily 0.8 https://www.321223.com/media/4tejef2g/2025-interim-report-c.pdf 2026-11-11 06:43:45 daily 0.8 https://www.321223.com/media/4hyptsvx/ct1190b-ps2064_ye-1.pdf 2026-11-11 06:43:25 daily 0.8 https://www.321223.com/media/4cbfepok/hkex-eps_20260915_12332733_0.pdf 2026-11-11 06:43:05 daily 0.8 https://www.321223.com/media/3vsj00ph/2024-annual-report.pdf 2026-11-11 06:42:45 daily 0.8 https://www.321223.com/media/3bzk0o35/hkex-eps_20260522_12169561_0.pdf 2026-11-11 06:42:25 daily 0.8 https://www.321223.com/media/3byc3vpp/hkex-eps_20230419_10692750_0_hk.pdf 2026-11-11 06:42:05 daily 0.8 https://www.321223.com/media/2w4bh31e/procedures-for-shareholders-to-propose-directors-cn.pdf 2026-11-11 06:41:45 daily 0.8 https://www.321223.com/media/2rwlk1zn/final-carsgen-therapeutics-corporate-deck_oct-13.pdf 2026-11-11 06:41:25 daily 0.8 https://www.321223.com/media/2kygbdc3/final-p941_du.pdf 2026-11-11 06:41:05 daily 0.8 https://www.321223.com/media/1w1dumr5/final-ims_poster_pa-029_id-number-3173032-v2-1.pdf 2026-11-11 06:40:45 daily 0.8 https://www.321223.com/media/1s3dnn3g/blue-asco-poster-gpb-05-19-2023-final.pdf 2026-11-11 06:40:25 daily 0.8 https://www.321223.com/media/1rjd2yul/hkex-eps_20260410_12102281_0.pdf 2026-11-11 06:40:05 daily 0.8 https://www.321223.com/media/1gwa3sdq/ct041-st-02-phase-1b-cohort-a-2024-asco-gi-poster_final.pdf 2026-11-11 06:39:45 daily 0.8 https://www.321223.com/media/0yylooxm/ct071-ash-poster_-3451.pdf 2026-11-11 06:39:25 daily 0.8 https://www.321223.com/media/0klf3v3t/ct041-st-01-abs4017-poster_final.pdf 2026-11-11 06:39:05 daily 0.8 https://www.321223.com/lxwm/ 2026-11-11 06:38:45 daily 0.8 https://www.321223.com/jrwm/ 2026-11-11 06:38:25 daily 0.8 https://www.321223.com/jjfa/ 2026-11-11 06:38:05 daily 0.8 https://www.321223.com/html/web/xinwenzhongxin/shipinzhuanqu/index.html 2026-11-11 06:37:45 daily 0.8 https://www.321223.com/html/web/xinwenzhongxin/fangdaxinwen/index.html 2026-11-11 06:37:25 daily 0.8 https://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/index.html 2026-11-11 06:37:05 daily 0.8 https://www.321223.com/html/web/touziyuhezuo/shangshigongsi/index.html 2026-11-11 06:36:45 daily 0.8 https://www.321223.com/html/web/shehuizeren/zhichiguofang/index.html 2026-11-11 06:36:25 daily 0.8 https://www.321223.com/html/web/shehuizeren/yifanashui/index.html 2026-11-11 06:36:05 daily 0.8 https://www.321223.com/html/web/shehuizeren/shehuigongyi/index.html 2026-11-11 06:35:45 daily 0.8 https://www.321223.com/html/web/shehuizeren/jienenghuanbao/index.html 2026-11-11 06:35:25 daily 0.8 https://www.321223.com/html/web/shehuizeren/baozhangjiuye/index.html 2026-11-11 06:35:05 daily 0.8 https://www.321223.com/html/web/rencaifazhan/zhaopingonggao/index.html 2026-11-11 06:34:45 daily 0.8 https://www.321223.com/html/web/guanyuwomen/zuzhijiagou/index.html 2026-11-11 06:34:25 daily 0.8 https://www.321223.com/html/web/guanyuwomen/fazhanlicheng/index.html 2026-11-11 06:34:05 daily 0.8 https://www.321223.com/html/web/guanyuwomen/fangdarongyu/index.html 2026-11-11 06:33:45 daily 0.8 https://www.321223.com/html/web/guanyuwomen/fangdajianjie/index.html 2026-11-11 06:33:25 daily 0.8 https://www.321223.com/html/web/dangjianwenhua/xingfufangda/index.html 2026-11-11 06:33:05 daily 0.8 https://www.321223.com/html/web/dangjianwenhua/qiyelinian/index.html 2026-11-11 06:32:45 daily 0.8 https://www.321223.com/html/web/dangjianwenhua/dangqunhuodong/index.html 2026-11-11 06:32:25 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/yiyao/index.html 2026-11-11 06:32:05 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/tansu/index.html 2026-11-11 06:31:45 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/shangye/index.html 2026-11-11 06:31:25 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/hangkong/index.html 2026-11-11 06:31:05 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/gangtie/index.html 2026-11-11 06:30:45 daily 0.8 https://www.321223.com/hk/privacy-policy/ 2026-11-11 06:30:25 daily 0.8 https://www.321223.com/hk/pipeline/ 2026-11-11 06:30:05 daily 0.8 https://www.321223.com/hk/our-approach/technologies/ 2026-11-11 06:29:45 daily 0.8 https://www.321223.com/hk/our-approach/publications/?page=1 2026-11-11 06:29:25 daily 0.8 https://www.321223.com/hk/our-approach/publications/ 2026-11-11 06:29:05 daily 0.8 https://www.321223.com/hk/our-approach/manufacturing/ 2026-11-11 06:28:45 daily 0.8 https://www.321223.com/hk/our-approach/ 2026-11-11 06:28:25 daily 0.8 https://www.321223.com/hk/news/�Ƽ�ҩҵct041����asco-�״ι�������ע���ٴ���������/ 2026-11-11 06:28:05 daily 0.8 https://www.321223.com/hk/news/?page=4 2026-11-11 06:27:45 daily 0.8 https://www.321223.com/hk/news/?page=3 2026-11-11 06:27:25 daily 0.8 https://www.321223.com/hk/news/?page=2 2026-11-11 06:27:05 daily 0.8 https://www.321223.com/hk/news/?page=1 2026-11-11 06:26:45 daily 0.8 https://www.321223.com/hk/news/20191209/ 2026-11-11 06:26:25 daily 0.8 https://www.321223.com/hk/news/20190301/ 2026-11-11 06:26:05 daily 0.8 https://www.321223.com/hk/news/20190129/ 2026-11-11 06:25:45 daily 0.8 https://www.321223.com/hk/news/20190128/ 2026-11-11 06:25:25 daily 0.8 https://www.321223.com/hk/news/20180302/ 2026-11-11 06:25:05 daily 0.8 https://www.321223.com/hk/news/20170810/ 2026-11-11 06:24:45 daily 0.8 https://www.321223.com/hk/news/ 2026-11-11 06:24:25 daily 0.8 https://www.321223.com/hk/investors/listing-documents/ 2026-11-11 06:24:05 daily 0.8 https://www.321223.com/hk/investors/ir-contact/ 2026-11-11 06:23:45 daily 0.8 https://www.321223.com/hk/investors/financial-reports/ 2026-11-11 06:23:25 daily 0.8 https://www.321223.com/hk/investors/corporate-governance/ 2026-11-11 06:23:05 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=5 2026-11-11 06:22:45 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=4 2026-11-11 06:22:25 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=3 2026-11-11 06:22:05 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=2 2026-11-11 06:21:45 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=1 2026-11-11 06:21:25 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/ 2026-11-11 06:21:05 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=5 2026-11-11 06:20:45 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=4 2026-11-11 06:20:25 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=3 2026-11-11 06:20:05 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=2 2026-11-11 06:19:45 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=1 2026-11-11 06:19:25 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/ 2026-11-11 06:19:05 daily 0.8 https://www.321223.com/hk/investors/announcements-circulars/ 2026-11-11 06:18:45 daily 0.8 https://www.321223.com/hk/investors/ 2026-11-11 06:18:25 daily 0.8 https://www.321223.com/hk/disclaimer/ 2026-11-11 06:18:05 daily 0.8 https://www.321223.com/hk/contact-us/ 2026-11-11 06:17:45 daily 0.8 https://www.321223.com/hk/careers/join-us/ 2026-11-11 06:17:25 daily 0.8 https://www.321223.com/hk/careers/ 2026-11-11 06:17:05 daily 0.8 https://www.321223.com/hk/about-us/vision-mission-values/ 2026-11-11 06:16:45 daily 0.8 https://www.321223.com/hk/about-us/partnering/ 2026-11-11 06:16:25 daily 0.8 https://www.321223.com/hk/about-us/company-overview/ 2026-11-11 06:16:05 daily 0.8 https://www.321223.com/hk/about-us/ 2026-11-11 06:15:45 daily 0.8 https://www.321223.com/hk/ 2026-11-11 06:15:25 daily 0.8 https://www.321223.com/gydk/ryzz/ 2026-11-11 06:15:05 daily 0.8 https://www.321223.com/gydk/qysl/ 2026-11-11 06:14:45 daily 0.8 https://www.321223.com/gydk/gywm/ 2026-11-11 06:14:25 daily 0.8 https://www.321223.com/en/privacy-policy/ 2026-11-11 06:14:05 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/kj-c2630/ 2026-11-11 06:13:45 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/kj-c2527/ 2026-11-11 06:13:25 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/kj-c2526/ 2026-11-11 06:13:05 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/ct1390b/ 2026-11-11 06:12:45 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/ct1190b-kj-c2219/ 2026-11-11 06:12:25 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/ct0596/ 2026-11-11 06:12:05 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/ 2026-11-11 06:11:45 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2635/ 2026-11-11 06:11:25 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2634/ 2026-11-11 06:11:05 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2633/ 2026-11-11 06:10:45 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2632/ 2026-11-11 06:10:25 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2529/ 2026-11-11 06:10:05 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/ 2026-11-11 06:09:45 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/zevor-cel-ct053-3/ 2026-11-11 06:09:25 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/ct041/ 2026-11-11 06:09:05 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/ 2026-11-11 06:08:45 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/ 2026-11-11 06:08:25 daily 0.8 https://www.321223.com/en/pipeline/expanded-access/ 2026-11-11 06:08:05 daily 0.8 https://www.321223.com/en/pipeline/ 2026-11-11 06:07:45 daily 0.8 https://www.321223.com/en/our-approach/technologies/ 2026-11-11 06:07:25 daily 0.8 https://www.321223.com/en/our-approach/publications/zevorcabtagene-autoleucel-first-approval/ 2026-11-11 06:07:05 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-κb-icam1-signaling/ 2026-11-11 06:06:45 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-��b-icam1-signaling/ 2026-11-11 06:06:25 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=5 2026-11-11 06:06:05 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=4 2026-11-11 06:05:45 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=2 2026-11-11 06:05:25 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=1 2026-11-11 06:05:05 daily 0.8 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=4 2026-11-11 06:04:45 daily 0.8 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=2 2026-11-11 06:04:25 daily 0.8 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=1 2026-11-11 06:04:05 daily 0.8 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/ 2026-11-11 06:03:45 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=5 2026-11-11 06:03:25 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=4 2026-11-11 06:03:05 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=2 2026-11-11 06:02:45 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=1 2026-11-11 06:02:25 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/ 2026-11-11 06:02:05 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=5 2026-11-11 06:01:45 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=4 2026-11-11 06:01:25 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=2 2026-11-11 06:01:05 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=1 2026-11-11 06:00:45 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/ 2026-11-11 06:00:25 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=5 2026-11-11 06:00:05 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=4 2026-11-11 05:59:45 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=2 2026-11-11 05:59:25 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=1 2026-11-11 05:59:05 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/ 2026-11-11 05:58:45 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=4 2026-11-11 05:58:25 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=2 2026-11-11 05:58:05 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=1 2026-11-11 05:57:45 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/ 2026-11-11 05:57:25 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3ε-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ 2026-11-11 05:57:05 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3��-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ 2026-11-11 05:56:45 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=5 2026-11-11 05:56:25 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=4 2026-11-11 05:56:05 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=2 2026-11-11 05:55:45 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=1 2026-11-11 05:55:25 daily 0.8 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=4 2026-11-11 05:55:05 daily 0.8 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=2 2026-11-11 05:54:45 daily 0.8 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=1 2026-11-11 05:54:25 daily 0.8 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/ 2026-11-11 05:54:05 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=5 2026-11-11 05:53:45 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=4 2026-11-11 05:53:25 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=3 2026-11-11 05:53:05 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=2 2026-11-11 05:52:45 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=1 2026-11-11 05:52:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20261001/ 2026-11-11 05:52:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/?page=5 2026-11-11 05:51:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/?page=4 2026-11-11 05:51:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/?page=2 2026-11-11 05:51:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/?page=1 2026-11-11 05:50:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/ 2026-11-11 05:50:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/?page=5 2026-11-11 05:50:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/?page=4 2026-11-11 05:49:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/?page=2 2026-11-11 05:49:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/?page=1 2026-11-11 05:49:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/ 2026-11-11 05:48:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20251008/?page=5 2026-11-11 05:48:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20251008/?page=4 2026-11-11 05:48:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20251008/?page=2 2026-11-11 05:47:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20251008/?page=1 2026-11-11 05:47:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20251008/ 2026-11-11 05:47:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20250930/?page=4 2026-11-11 05:46:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20250930/?page=2 2026-11-11 05:46:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20250930/?page=1 2026-11-11 05:46:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20250930/ 2026-11-11 05:45:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/?page=5 2026-11-11 05:45:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/?page=4 2026-11-11 05:45:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/?page=2 2026-11-11 05:44:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/?page=1 2026-11-11 05:44:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/ 2026-11-11 05:44:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/?page=5 2026-11-11 05:43:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/?page=4 2026-11-11 05:43:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/?page=2 2026-11-11 05:43:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/?page=1 2026-11-11 05:42:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/ 2026-11-11 05:42:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/?page=5 2026-11-11 05:42:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/?page=4 2026-11-11 05:41:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/?page=2 2026-11-11 05:41:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/?page=1 2026-11-11 05:41:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/ 2026-11-11 05:40:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/?page=5 2026-11-11 05:40:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/?page=4 2026-11-11 05:40:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/?page=2 2026-11-11 05:39:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/?page=1 2026-11-11 05:39:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/ 2026-11-11 05:39:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20230920/?page=5 2026-11-11 05:38:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20230920/?page=4 2026-11-11 05:38:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20230920/?page=2 2026-11-11 05:38:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20230920/?page=1 2026-11-11 05:37:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20230920/ 2026-11-11 05:37:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/?page=5 2026-11-11 05:37:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/?page=4 2026-11-11 05:36:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/?page=2 2026-11-11 05:36:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/?page=1 2026-11-11 05:36:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/ 2026-11-11 05:35:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/?page=5 2026-11-11 05:35:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/?page=4 2026-11-11 05:35:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/?page=2 2026-11-11 05:34:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/?page=1 2026-11-11 05:34:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/ 2026-11-11 05:34:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20221215/?page=5 2026-11-11 05:33:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20221215/?page=4 2026-11-11 05:33:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20221215/?page=2 2026-11-11 05:33:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20221215/?page=1 2026-11-11 05:32:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20221215/ 2026-11-11 05:32:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20220817/?page=5 2026-11-11 05:32:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20220817/?page=4 2026-11-11 05:31:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20220817/?page=2 2026-11-11 05:31:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20220817/?page=1 2026-11-11 05:31:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20220817/ 2026-11-11 05:30:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/?page=5 2026-11-11 05:30:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/?page=4 2026-11-11 05:30:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/?page=2 2026-11-11 05:29:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/?page=1 2026-11-11 05:29:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/ 2026-11-11 05:29:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20200925/?page=5 2026-11-11 05:28:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20200925/?page=2 2026-11-11 05:28:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20200925/?page=1 2026-11-11 05:28:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20200925/ 2026-11-11 05:27:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20200801/?page=4 2026-11-11 05:27:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20200801/?page=2 2026-11-11 05:27:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20200801/?page=1 2026-11-11 05:26:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20200801/ 2026-11-11 05:26:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20200121/?page=4 2026-11-11 05:26:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20200121/?page=2 2026-11-11 05:25:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20200121/?page=1 2026-11-11 05:25:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20200121/ 2026-11-11 05:25:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20191219/?page=4 2026-11-11 05:24:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20191219/?page=2 2026-11-11 05:24:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20191219/?page=1 2026-11-11 05:24:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20191219/ 2026-11-11 05:23:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/?page=5 2026-11-11 05:23:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/?page=4 2026-11-11 05:23:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/?page=2 2026-11-11 05:22:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/?page=1 2026-11-11 05:22:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/ 2026-11-11 05:22:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20190701/?page=5 2026-11-11 05:21:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20190701/?page=4 2026-11-11 05:21:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20190701/?page=2 2026-11-11 05:21:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20190701/?page=1 2026-11-11 05:20:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20190701/ 2026-11-11 05:20:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20190429/ 2026-11-11 05:20:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20190417/?page=4 2026-11-11 05:19:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20190417/?page=2 2026-11-11 05:19:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20190417/?page=1 2026-11-11 05:19:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20190417/ 2026-11-11 05:18:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/?page=5 2026-11-11 05:18:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/?page=4 2026-11-11 05:18:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/?page=2 2026-11-11 05:17:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/?page=1 2026-11-11 05:17:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/ 2026-11-11 05:17:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/?page=5 2026-11-11 05:16:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/?page=4 2026-11-11 05:16:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/?page=2 2026-11-11 05:16:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/?page=1 2026-11-11 05:15:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/ 2026-11-11 05:15:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20180906/ 2026-11-11 05:15:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20180804/?page=4 2026-11-11 05:14:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20180804/?page=2 2026-11-11 05:14:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20180804/?page=1 2026-11-11 05:14:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20180804/ 2026-11-11 05:13:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20171218/?page=5 2026-11-11 05:13:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20171218/?page=4 2026-11-11 05:13:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20171218/?page=2 2026-11-11 05:12:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20171218/?page=1 2026-11-11 05:12:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20171218/ 2026-11-11 05:12:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20170919/?page=4 2026-11-11 05:11:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20170919/?page=2 2026-11-11 05:11:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20170919/?page=1 2026-11-11 05:11:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20170919/ 2026-11-11 05:10:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/?page=5 2026-11-11 05:10:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/?page=4 2026-11-11 05:10:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/?page=2 2026-11-11 05:09:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/?page=1 2026-11-11 05:09:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/ 2026-11-11 05:09:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20170516/?page=4 2026-11-11 05:08:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20170516/?page=2 2026-11-11 05:08:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20170516/?page=1 2026-11-11 05:08:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20170516/ 2026-11-11 05:07:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/?page=5 2026-11-11 05:07:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/?page=4 2026-11-11 05:07:05 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/?page=2 2026-11-11 05:06:45 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/?page=1 2026-11-11 05:06:25 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/ 2026-11-11 05:06:05 daily 0.8 https://www.321223.com/en/our-approach/publications/ 2026-11-11 05:05:25 daily 0.8 https://www.321223.com/en/our-approach/manufacturing/ 2026-11-11 05:05:05 daily 0.8 https://www.321223.com/en/our-approach/ 2026-11-11 05:04:45 daily 0.8 https://www.321223.com/en/news/�Ƽ�ҩҵ������-ii���ٴ������ct071�״�����������о��ɹ�����2024-eha/ 2026-11-11 05:04:25 daily 0.8 https://www.321223.com/en/news/carsgen-presents-updated-results-on-satri-cel-in-nature-medicine-and-at-2024-asco/ 2026-11-11 05:04:05 daily 0.8 https://www.321223.com/en/news/carsgen-presents-first-in-human-results-of-gprc5d-targeting-car-t-ct071-at-eha-2024/ 2026-11-11 05:03:45 daily 0.8 https://www.321223.com/en/news/?page=2 2026-11-11 05:03:25 daily 0.8 https://www.321223.com/en/news/?page=14 2026-11-11 05:03:05 daily 0.8 https://www.321223.com/en/news/?page=13 2026-11-11 05:02:45 daily 0.8 https://www.321223.com/en/news/?page=1 2026-11-11 05:02:25 daily 0.8 https://www.321223.com/en/news/20261105/ 2026-11-11 05:02:05 daily 0.8 https://www.321223.com/en/news/20261026/ 2026-11-11 05:01:45 daily 0.8 https://www.321223.com/en/news/20261013/ 2026-11-11 05:01:25 daily 0.8 https://www.321223.com/en/news/20260929/ 2026-11-11 05:01:05 daily 0.8 https://www.321223.com/en/news/20260819/ 2026-11-11 05:00:45 daily 0.8 https://www.321223.com/en/news/20260807/ 2026-11-11 05:00:25 daily 0.8 https://www.321223.com/en/news/20260804/ 2026-11-11 05:00:05 daily 0.8 https://www.321223.com/en/news/20260715/ 2026-11-11 04:59:45 daily 0.8 https://www.321223.com/en/news/20260622/ 2026-11-11 04:59:25 daily 0.8 https://www.321223.com/en/news/20260615/ 2026-11-11 04:59:05 daily 0.8 https://www.321223.com/en/news/20260601/ 2026-11-11 04:58:45 daily 0.8 https://www.321223.com/en/news/20260521/ 2026-11-11 04:58:25 daily 0.8 https://www.321223.com/en/news/20260512/ 2026-11-11 04:58:05 daily 0.8 https://www.321223.com/en/news/20260428/ 2026-11-11 04:57:45 daily 0.8 https://www.321223.com/en/news/20260309/ 2026-11-11 04:57:25 daily 0.8 https://www.321223.com/en/news/20260306/ 2026-11-11 04:57:05 daily 0.8 https://www.321223.com/en/news/20260213/ 2026-11-11 04:56:45 daily 0.8 https://www.321223.com/en/news/20260112/ 2026-11-11 04:56:25 daily 0.8 https://www.321223.com/en/news/20251229/ 2026-11-11 04:56:05 daily 0.8 https://www.321223.com/en/news/20250625/ 2026-11-11 04:55:45 daily 0.8 https://www.321223.com/en/news/20250120/ 2026-11-11 04:55:25 daily 0.8 https://www.321223.com/en/news/20250113/ 2026-11-11 04:55:05 daily 0.8 https://www.321223.com/en/news/20241231/ 2026-11-11 04:54:45 daily 0.8 https://www.321223.com/en/news/2023-08-21/ 2026-11-11 04:54:25 daily 0.8 https://www.321223.com/en/news/20220921/ 2026-11-11 04:54:05 daily 0.8 https://www.321223.com/en/news/20190301/ 2026-11-11 04:53:45 daily 0.8 https://www.321223.com/en/news/20190129/ 2026-11-11 04:53:25 daily 0.8 https://www.321223.com/en/news/20181204/ 2026-11-11 04:53:05 daily 0.8 https://www.321223.com/en/news/ 2026-11-11 04:52:45 daily 0.8 https://www.321223.com/en/investors/listing-documents/ 2026-11-11 04:52:25 daily 0.8 https://www.321223.com/en/investors/ir-contact/ 2026-11-11 04:52:05 daily 0.8 https://www.321223.com/en/investors/financial-reports/ 2026-11-11 04:51:45 daily 0.8 https://www.321223.com/en/investors/corporate-governance/ 2026-11-11 04:51:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=6 2026-11-11 04:51:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=5 2026-11-11 04:50:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=4 2026-11-11 04:50:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=3 2026-11-11 04:50:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=2 2026-11-11 04:49:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=1 2026-11-11 04:49:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/ 2026-11-11 04:49:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=6 2026-11-11 04:48:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=5 2026-11-11 04:48:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=4 2026-11-11 04:48:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=3 2026-11-11 04:47:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=2 2026-11-11 04:47:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=1 2026-11-11 04:47:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/ 2026-11-11 04:46:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=6 2026-11-11 04:46:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=5 2026-11-11 04:46:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=4 2026-11-11 04:45:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=3 2026-11-11 04:45:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=2 2026-11-11 04:45:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=1 2026-11-11 04:44:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20261026/ 2026-11-11 04:44:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=5 2026-11-11 04:44:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=4 2026-11-11 04:43:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=3 2026-11-11 04:43:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=2 2026-11-11 04:43:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=1 2026-11-11 04:42:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/ 2026-11-11 04:42:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=5 2026-11-11 04:42:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=4 2026-11-11 04:41:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=3 2026-11-11 04:41:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=2 2026-11-11 04:41:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=1 2026-11-11 04:40:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/ 2026-11-11 04:40:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=6 2026-11-11 04:40:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=5 2026-11-11 04:39:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=4 2026-11-11 04:39:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=3 2026-11-11 04:39:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=2 2026-11-11 04:38:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=1 2026-11-11 04:38:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/ 2026-11-11 04:38:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=6 2026-11-11 04:37:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=5 2026-11-11 04:37:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=4 2026-11-11 04:37:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=3 2026-11-11 04:36:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=2 2026-11-11 04:36:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=1 2026-11-11 04:36:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/ 2026-11-11 04:35:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=5 2026-11-11 04:35:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=4 2026-11-11 04:35:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=3 2026-11-11 04:34:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=2 2026-11-11 04:34:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=1 2026-11-11 04:34:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/ 2026-11-11 04:33:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 2026-11-11 04:33:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-11 04:33:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-11 04:32:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-11 04:32:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-11 04:32:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-11 04:31:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-11 04:31:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=6 2026-11-11 04:31:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=5 2026-11-11 04:30:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=4 2026-11-11 04:30:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=3 2026-11-11 04:30:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=2 2026-11-11 04:29:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=1 2026-11-11 04:29:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/ 2026-11-11 04:29:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=6 2026-11-11 04:28:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=5 2026-11-11 04:28:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=4 2026-11-11 04:28:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=3 2026-11-11 04:27:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=2 2026-11-11 04:27:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=1 2026-11-11 04:27:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/ 2026-11-11 04:26:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-asco-claudin18-2-specific-car-t-cells-satri-cel-versus-treatment-of-physician-s-choice-tpc-for-previously-treated-advanced-gastric-or-gastroesophageal-junction-cancer-g-gejc-primary-results-from-a-randomized-open-label-phase-ii-trial-c/ 2026-11-11 04:26:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=6 2026-11-11 04:26:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=5 2026-11-11 04:25:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=4 2026-11-11 04:25:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=3 2026-11-11 04:25:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=2 2026-11-11 04:24:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=1 2026-11-11 04:24:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/ 2026-11-11 04:24:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-11 04:23:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-11 04:23:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-11 04:23:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-11 04:22:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-11 04:22:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-11 04:22:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=5 2026-11-11 04:21:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=4 2026-11-11 04:21:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=3 2026-11-11 04:21:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=2 2026-11-11 04:20:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=1 2026-11-11 04:20:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/ 2026-11-11 04:20:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=5 2026-11-11 04:19:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=4 2026-11-11 04:19:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=3 2026-11-11 04:19:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=2 2026-11-11 04:18:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=1 2026-11-11 04:18:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/ 2026-11-11 04:18:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=5 2026-11-11 04:17:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=4 2026-11-11 04:17:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=3 2026-11-11 04:17:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=2 2026-11-11 04:16:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=1 2026-11-11 04:16:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/ 2026-11-11 04:16:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=6 2026-11-11 04:15:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=5 2026-11-11 04:15:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=4 2026-11-11 04:15:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=3 2026-11-11 04:14:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=2 2026-11-11 04:14:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=1 2026-11-11 04:14:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/ 2026-11-11 04:13:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/ 2026-11-11 04:13:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=6 2026-11-11 04:13:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=5 2026-11-11 04:12:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=4 2026-11-11 04:12:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=3 2026-11-11 04:12:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=2 2026-11-11 04:11:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=1 2026-11-11 04:11:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/ 2026-11-11 04:11:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=6 2026-11-11 04:10:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=5 2026-11-11 04:10:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=4 2026-11-11 04:10:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=3 2026-11-11 04:09:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=2 2026-11-11 04:09:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=1 2026-11-11 04:09:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/ 2026-11-11 04:08:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-gi-a-multicenter-phase-1-study-of-ab011-a-recombinant-humanized-anti-cldn18-2-monoclonal-antibody-ab011-as-monotherapy-and-combined-with-capecitabine-and-oxaliplatin-capox-in-patients-with-advanced-solid-tumors/ 2026-11-11 04:08:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=6 2026-11-11 04:08:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=5 2026-11-11 04:07:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=4 2026-11-11 04:07:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=3 2026-11-11 04:07:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=2 2026-11-11 04:06:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=1 2026-11-11 04:06:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/ 2026-11-11 04:06:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=5 2026-11-11 04:05:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=4 2026-11-11 04:05:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=3 2026-11-11 04:05:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=2 2026-11-11 04:04:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=1 2026-11-11 04:04:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/ 2026-11-11 04:04:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=6 2026-11-11 04:03:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=5 2026-11-11 04:03:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=4 2026-11-11 04:03:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=3 2026-11-11 04:02:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=2 2026-11-11 04:02:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=1 2026-11-11 04:02:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/ 2026-11-11 04:01:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=6 2026-11-11 04:01:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=5 2026-11-11 04:01:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=4 2026-11-11 04:00:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=3 2026-11-11 04:00:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=2 2026-11-11 04:00:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=1 2026-11-11 03:59:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/ 2026-11-11 03:59:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 2026-11-11 03:59:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-11 03:58:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-11 03:58:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-11 03:58:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-11 03:57:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-11 03:57:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-11 03:57:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=5 2026-11-11 03:56:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=4 2026-11-11 03:56:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=3 2026-11-11 03:56:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=2 2026-11-11 03:55:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=1 2026-11-11 03:55:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/ 2026-11-11 03:55:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=6 2026-11-11 03:54:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=5 2026-11-11 03:54:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=4 2026-11-11 03:54:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=3 2026-11-11 03:53:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=2 2026-11-11 03:53:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=1 2026-11-11 03:53:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/ 2026-11-11 03:52:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=6 2026-11-11 03:52:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=5 2026-11-11 03:52:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=4 2026-11-11 03:51:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=3 2026-11-11 03:51:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=2 2026-11-11 03:51:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=1 2026-11-11 03:50:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/ 2026-11-11 03:50:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=6 2026-11-11 03:50:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=5 2026-11-11 03:49:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=4 2026-11-11 03:49:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=3 2026-11-11 03:49:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=2 2026-11-11 03:48:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=1 2026-11-11 03:48:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/ 2026-11-11 03:48:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=6 2026-11-11 03:47:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=5 2026-11-11 03:47:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=4 2026-11-11 03:47:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=3 2026-11-11 03:46:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=2 2026-11-11 03:46:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=1 2026-11-11 03:46:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/ 2026-11-11 03:45:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/ 2026-11-11 03:45:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=6 2026-11-11 03:45:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=5 2026-11-11 03:44:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=4 2026-11-11 03:44:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=3 2026-11-11 03:44:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=2 2026-11-11 03:43:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=1 2026-11-11 03:43:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/ 2026-11-11 03:43:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=5 2026-11-11 03:42:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=4 2026-11-11 03:42:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=3 2026-11-11 03:42:05 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=2 2026-11-11 03:41:45 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=1 2026-11-11 03:41:25 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/ 2026-11-11 03:41:05 daily 0.8 https://www.321223.com/en/investors/announcements-circulars/ 2026-11-11 03:40:45 daily 0.8 https://www.321223.com/en/investors/ 2026-11-11 03:40:25 daily 0.8 https://www.321223.com/en/disclaimer/ 2026-11-11 03:40:05 daily 0.8 https://www.321223.com/en/contact-us/ 2026-11-11 03:39:45 daily 0.8 https://www.321223.com/en/careers/join-us/ 2026-11-11 03:39:25 daily 0.8 https://www.321223.com/en/careers/ 2026-11-11 03:39:05 daily 0.8 https://www.321223.com/en/about-us/vision-mission-values/ 2026-11-11 03:38:45 daily 0.8 https://www.321223.com/en/about-us/partnering/ 2026-11-11 03:38:25 daily 0.8 https://www.321223.com/en/about-us/leadership/ 2026-11-11 03:38:05 daily 0.8 https://www.321223.com/en/about-us/company-overview/ 2026-11-11 03:37:45 daily 0.8 https://www.321223.com/en/about-us/ 2026-11-11 03:37:25 daily 0.8 https://www.321223.com/en/" 2026-11-11 03:37:05 daily 0.8 https://www.321223.com/en/ 2026-11-11 03:36:45 daily 0.8 https://www.321223.com/cpzs/html/179.html 2026-11-11 03:36:25 daily 0.8 https://www.321223.com/cpzs/html/178.html 2026-11-11 03:36:05 daily 0.8 https://www.321223.com/cpzs/html/177.html 2026-11-11 03:35:45 daily 0.8 https://www.321223.com/cpzs/html/176.html 2026-11-11 03:35:25 daily 0.8 https://www.321223.com/cpzs/html/174.html 2026-11-11 03:35:05 daily 0.8 https://www.321223.com/cpzs/html/173.html 2026-11-11 03:34:45 daily 0.8 https://www.321223.com/cpzs/html/172.html 2026-11-11 03:34:25 daily 0.8 https://www.321223.com/cpzs/html/171.html 2026-11-11 03:34:05 daily 0.8 https://www.321223.com/cpzs/html/170.html 2026-11-11 03:33:45 daily 0.8 https://www.321223.com/cpzs/html/169.html 2026-11-11 03:33:25 daily 0.8 https://www.321223.com/cpzs/html/168.html 2026-11-11 03:33:05 daily 0.8 https://www.321223.com/cpzs/html/167.html 2026-11-11 03:32:45 daily 0.8 https://www.321223.com/cpzs/html/166.html 2026-11-11 03:32:25 daily 0.8 https://www.321223.com/cpzs/ 2026-11-11 03:32:05 daily 0.8 https://www.321223.com/cn/privacy-policy/ 2026-11-11 03:31:25 daily 0.8 https://www.321223.com/cn/pipeline/zevor-cel/ 2026-11-11 03:30:45 daily 0.8 https://www.321223.com/cn/pipeline/satri-cel/ 2026-11-11 03:30:05 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/kj-c2630/ 2026-11-11 03:29:25 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/kj-c2527/ 2026-11-11 03:28:45 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/kj-c2526/ 2026-11-11 03:28:05 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/ct1390b/ 2026-11-11 03:27:25 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/ct1190b-kj-c2219/ 2026-11-11 03:26:45 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/ct0596/ 2026-11-11 03:26:05 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/ 2026-11-11 03:25:25 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2635/ 2026-11-11 03:24:45 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2634/ 2026-11-11 03:24:05 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2633/ 2026-11-11 03:23:25 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2632/ 2026-11-11 03:22:45 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2529/ 2026-11-11 03:22:05 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/ 2026-11-11 03:21:25 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/zevor-cel-ct053-3/ 2026-11-11 03:20:45 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/ct041/ 2026-11-11 03:20:05 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/ 2026-11-11 03:19:25 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/ 2026-11-11 03:18:45 daily 0.8 https://www.321223.com/cn/pipeline/expanded-access/ 2026-11-11 03:18:25 daily 0.8 https://www.321223.com/cn/pipeline/ 2026-11-11 03:17:45 daily 0.8 https://www.321223.com/cn/our-approach/technologies/ 2026-11-11 03:17:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=5 2026-11-11 03:16:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=4 2026-11-11 03:16:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=2 2026-11-11 03:16:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=1 2026-11-11 03:15:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/ 2026-11-11 03:15:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-κb-icam1-signaling/ 2026-11-11 03:14:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-��b-icam1-signaling/ 2026-11-11 03:14:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=5 2026-11-11 03:13:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=4 2026-11-11 03:13:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=2 2026-11-11 03:13:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=1 2026-11-11 03:12:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=4 2026-11-11 03:12:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=2 2026-11-11 03:12:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=1 2026-11-11 03:11:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/ 2026-11-11 03:11:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=5 2026-11-11 03:10:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=4 2026-11-11 03:10:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=2 2026-11-11 03:10:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=1 2026-11-11 03:09:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/ 2026-11-11 03:09:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=5 2026-11-11 03:08:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=4 2026-11-11 03:08:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=2 2026-11-11 03:08:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=1 2026-11-11 03:07:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/ 2026-11-11 03:07:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=5 2026-11-11 03:06:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=4 2026-11-11 03:06:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=2 2026-11-11 03:06:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=1 2026-11-11 03:05:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/ 2026-11-11 03:05:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=5 2026-11-11 03:04:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=4 2026-11-11 03:04:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=2 2026-11-11 03:04:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=1 2026-11-11 03:03:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/ 2026-11-11 03:03:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3ε-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ 2026-11-11 03:02:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3��-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ 2026-11-11 03:02:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=4 2026-11-11 03:01:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=2 2026-11-11 03:01:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=1 2026-11-11 03:01:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=5 2026-11-11 03:00:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=4 2026-11-11 03:00:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=2 2026-11-11 03:00:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=1 2026-11-11 02:59:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/ 2026-11-11 02:59:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=5 2026-11-11 02:58:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=4 2026-11-11 02:58:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=3 2026-11-11 02:58:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=2 2026-11-11 02:57:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=1 2026-11-11 02:57:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20261001/ 2026-11-11 02:56:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20260918/?page=4 2026-11-11 02:56:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20260918/?page=2 2026-11-11 02:56:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20260918/?page=1 2026-11-11 02:55:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20260918/ 2026-11-11 02:55:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251029/?page=5 2026-11-11 02:54:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251029/?page=4 2026-11-11 02:54:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251029/?page=2 2026-11-11 02:54:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251029/?page=1 2026-11-11 02:53:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251029/ 2026-11-11 02:53:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251008/?page=5 2026-11-11 02:52:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251008/?page=4 2026-11-11 02:52:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251008/?page=2 2026-11-11 02:52:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251008/?page=1 2026-11-11 02:51:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251008/ 2026-11-11 02:51:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/?page=5 2026-11-11 02:50:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/?page=4 2026-11-11 02:50:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/?page=2 2026-11-11 02:50:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/?page=1 2026-11-11 02:49:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/ 2026-11-11 02:49:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/?page=5 2026-11-11 02:48:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/?page=4 2026-11-11 02:48:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/?page=2 2026-11-11 02:48:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/?page=1 2026-11-11 02:47:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/ 2026-11-11 02:47:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/?page=5 2026-11-11 02:46:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/?page=4 2026-11-11 02:46:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/?page=2 2026-11-11 02:46:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/?page=1 2026-11-11 02:45:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/ 2026-11-11 02:45:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240311/?page=4 2026-11-11 02:44:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240311/?page=2 2026-11-11 02:44:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240311/?page=1 2026-11-11 02:44:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240311/ 2026-11-11 02:43:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/?page=5 2026-11-11 02:43:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/?page=4 2026-11-11 02:42:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/?page=2 2026-11-11 02:42:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/?page=1 2026-11-11 02:42:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/ 2026-11-11 02:41:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/?page=5 2026-11-11 02:41:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/?page=4 2026-11-11 02:40:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/?page=2 2026-11-11 02:40:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/?page=1 2026-11-11 02:40:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/ 2026-11-11 02:39:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/?page=5 2026-11-11 02:39:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/?page=4 2026-11-11 02:38:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/?page=2 2026-11-11 02:38:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/?page=1 2026-11-11 02:38:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/ 2026-11-11 02:37:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230830/?page=4 2026-11-11 02:37:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230830/?page=2 2026-11-11 02:36:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230830/?page=1 2026-11-11 02:36:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230830/ 2026-11-11 02:35:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/?page=5 2026-11-11 02:35:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/?page=4 2026-11-11 02:35:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/?page=2 2026-11-11 02:34:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/?page=1 2026-11-11 02:34:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/ 2026-11-11 02:33:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20220817/?page=4 2026-11-11 02:33:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20220817/?page=2 2026-11-11 02:33:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20220817/?page=1 2026-11-11 02:32:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20220817/ 2026-11-11 02:32:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/?page=5 2026-11-11 02:31:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/?page=4 2026-11-11 02:31:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/?page=2 2026-11-11 02:31:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/?page=1 2026-11-11 02:30:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/ 2026-11-11 02:30:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/?page=5 2026-11-11 02:29:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/?page=4 2026-11-11 02:29:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/?page=2 2026-11-11 02:29:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/?page=1 2026-11-11 02:28:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/ 2026-11-11 02:28:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/?page=5 2026-11-11 02:27:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/?page=4 2026-11-11 02:27:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/?page=2 2026-11-11 02:26:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/?page=1 2026-11-11 02:25:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/ 2026-11-11 02:25:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/?page=5 2026-11-11 02:24:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/?page=4 2026-11-11 02:24:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/?page=2 2026-11-11 02:24:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/?page=1 2026-11-11 02:23:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/ 2026-11-11 02:23:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/?page=5 2026-11-11 02:22:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/?page=4 2026-11-11 02:22:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/?page=2 2026-11-11 02:22:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/?page=1 2026-11-11 02:21:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/ 2026-11-11 02:21:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/?page=5 2026-11-11 02:20:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/?page=4 2026-11-11 02:20:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/?page=2 2026-11-11 02:20:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/?page=1 2026-11-11 02:19:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/ 2026-11-11 02:19:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190701/?page=4 2026-11-11 02:18:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190701/?page=2 2026-11-11 02:18:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190701/?page=1 2026-11-11 02:18:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190701/ 2026-11-11 02:17:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/?page=5 2026-11-11 02:17:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/?page=4 2026-11-11 02:16:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/?page=2 2026-11-11 02:16:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/?page=1 2026-11-11 02:16:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/ 2026-11-11 02:15:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190417/?page=5 2026-11-11 02:15:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190417/?page=4 2026-11-11 02:14:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190417/?page=2 2026-11-11 02:14:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190417/?page=1 2026-11-11 02:14:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190417/ 2026-11-11 02:13:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/?page=5 2026-11-11 02:13:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/?page=4 2026-11-11 02:12:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/?page=2 2026-11-11 02:12:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/?page=1 2026-11-11 02:12:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/ 2026-11-11 02:11:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181001/?page=5 2026-11-11 02:11:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181001/?page=4 2026-11-11 02:10:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181001/?page=2 2026-11-11 02:10:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181001/?page=1 2026-11-11 02:10:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181001/ 2026-11-11 02:09:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180906/?page=4 2026-11-11 02:09:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180906/?page=2 2026-11-11 02:08:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180906/?page=1 2026-11-11 02:08:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180906/ 2026-11-11 02:07:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180804/?page=4 2026-11-11 02:07:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180804/?page=2 2026-11-11 02:07:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180804/?page=1 2026-11-11 02:06:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180804/ 2026-11-11 02:06:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/?page=5 2026-11-11 02:05:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/?page=4 2026-11-11 02:05:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/?page=2 2026-11-11 02:05:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/?page=1 2026-11-11 02:04:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/ 2026-11-11 02:04:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/?page=5 2026-11-11 02:03:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/?page=4 2026-11-11 02:03:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/?page=2 2026-11-11 02:03:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/?page=1 2026-11-11 02:02:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/ 2026-11-11 02:02:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/?page=5 2026-11-11 02:01:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/?page=4 2026-11-11 02:01:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/?page=2 2026-11-11 02:01:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/?page=1 2026-11-11 02:00:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/ 2026-11-11 02:00:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170516/?page=4 2026-11-11 01:59:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170516/?page=2 2026-11-11 01:59:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170516/?page=1 2026-11-11 01:59:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170516/ 2026-11-11 01:58:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20161229/?page=5 2026-11-11 01:58:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20161229/?page=4 2026-11-11 01:57:45 daily 0.8 https://www.321223.com/cn/our-approach/publications/20161229/?page=2 2026-11-11 01:57:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/20161229/?page=1 2026-11-11 01:57:05 daily 0.8 https://www.321223.com/cn/our-approach/publications/20161229/ 2026-11-11 01:56:25 daily 0.8 https://www.321223.com/cn/our-approach/publications/ 2026-11-11 01:55:45 daily 0.8 https://www.321223.com/cn/our-approach/manufacturing/ 2026-11-11 01:55:05 daily 0.8 https://www.321223.com/cn/our-approach/ 2026-11-11 01:54:25 daily 0.8 https://www.321223.com/cn/news/Z6尊龙凯时药业美国cgmp出产工厂实现首例car-t产品的临床批次出产/ 2026-11-11 01:54:05 daily 0.8 https://www.321223.com/cn/news/Z6尊龙凯时药业bcma-car-t泽沃基奥仑赛注射液-ct053-新药上市申请获国度药监局受理/ 2026-11-11 01:53:45 daily 0.8 https://www.321223.com/cn/news/?page=4 2026-11-11 01:53:25 daily 0.8 https://www.321223.com/cn/news/?page=3 2026-11-11 01:53:05 daily 0.8 https://www.321223.com/cn/news/?page=21 2026-11-11 01:52:45 daily 0.8 https://www.321223.com/cn/news/?page=20 2026-11-11 01:52:25 daily 0.8 https://www.321223.com/cn/news/?page=2 2026-11-11 01:52:05 daily 0.8 https://www.321223.com/cn/news/?page=19 2026-11-11 01:51:45 daily 0.8 https://www.321223.com/cn/news/?page=18 2026-11-11 01:51:25 daily 0.8 https://www.321223.com/cn/news/?page=1 2026-11-11 01:51:05 daily 0.8 https://www.321223.com/cn/news/20261009/ 2026-11-11 01:50:45 daily 0.8 https://www.321223.com/cn/news/20260929/ 2026-11-11 01:50:25 daily 0.8 https://www.321223.com/cn/news/20260921/ 2026-11-11 01:50:05 daily 0.8 https://www.321223.com/cn/news/20260914/ 2026-11-11 01:49:45 daily 0.8 https://www.321223.com/cn/news/20260819/ 2026-11-11 01:49:25 daily 0.8 https://www.321223.com/cn/news/20260807/ 2026-11-11 01:49:05 daily 0.8 https://www.321223.com/cn/news/20260804/ 2026-11-11 01:48:45 daily 0.8 https://www.321223.com/cn/news/20260724/ 2026-11-11 01:48:25 daily 0.8 https://www.321223.com/cn/news/20260722/ 2026-11-11 01:48:05 daily 0.8 https://www.321223.com/cn/news/20260716/ 2026-11-11 01:47:45 daily 0.8 https://www.321223.com/cn/news/20260715/ 2026-11-11 01:47:25 daily 0.8 https://www.321223.com/cn/news/20260707/ 2026-11-11 01:47:05 daily 0.8 https://www.321223.com/cn/news/20260622/ 2026-11-11 01:46:45 daily 0.8 https://www.321223.com/cn/news/20260622-1/ 2026-11-11 01:46:25 daily 0.8 https://www.321223.com/cn/news/20260615/ 2026-11-11 01:46:05 daily 0.8 https://www.321223.com/cn/news/20260601/ 2026-11-11 01:45:45 daily 0.8 https://www.321223.com/cn/news/20260521/ 2026-11-11 01:45:25 daily 0.8 https://www.321223.com/cn/news/20260512/ 2026-11-11 01:45:05 daily 0.8 https://www.321223.com/cn/news/20260429/ 2026-11-11 01:44:45 daily 0.8 https://www.321223.com/cn/news/20260428/ 2026-11-11 01:44:25 daily 0.8 https://www.321223.com/cn/news/20260309/ 2026-11-11 01:44:05 daily 0.8 https://www.321223.com/cn/news/20260306/ 2026-11-11 01:43:45 daily 0.8 https://www.321223.com/cn/news/20260213/ 2026-11-11 01:43:25 daily 0.8 https://www.321223.com/cn/news/20260112/ 2026-11-11 01:43:05 daily 0.8 https://www.321223.com/cn/news/20251230/ 2026-11-11 01:42:45 daily 0.8 https://www.321223.com/cn/news/20251229/ 2026-11-11 01:42:25 daily 0.8 https://www.321223.com/cn/news/20251208/ 2026-11-11 01:42:05 daily 0.8 https://www.321223.com/cn/news/20251207/ 2026-11-11 01:41:45 daily 0.8 https://www.321223.com/cn/news/20251120/ 2026-11-11 01:41:25 daily 0.8 https://www.321223.com/cn/news/20251119/ 2026-11-11 01:41:05 daily 0.8 https://www.321223.com/cn/news/20250626/ 2026-11-11 01:40:45 daily 0.8 https://www.321223.com/cn/news/20250625/ 2026-11-11 01:40:25 daily 0.8 https://www.321223.com/cn/news/20250617/ 2026-11-11 01:40:05 daily 0.8 https://www.321223.com/cn/news/20250113/ 2026-11-11 01:39:45 daily 0.8 https://www.321223.com/cn/news/20220921/ 2026-11-11 01:39:25 daily 0.8 https://www.321223.com/cn/news/20211117/ 2026-11-11 01:39:05 daily 0.8 https://www.321223.com/cn/news/20211115/ 2026-11-11 01:38:45 daily 0.8 https://www.321223.com/cn/news/20211113/ 2026-11-11 01:38:25 daily 0.8 https://www.321223.com/cn/news/20190129/ 2026-11-11 01:38:05 daily 0.8 https://www.321223.com/cn/news/20180302/ 2026-11-11 01:37:45 daily 0.8 https://www.321223.com/cn/news/20170830/ 2026-11-11 01:37:25 daily 0.8 https://www.321223.com/cn/news/20170810/ 2026-11-11 01:37:05 daily 0.8 https://www.321223.com/cn/news/20170731/ 2026-11-11 01:36:45 daily 0.8 https://www.321223.com/cn/news/20170630/ 2026-11-11 01:36:25 daily 0.8 https://www.321223.com/cn/news/20170503/ 2026-11-11 01:36:05 daily 0.8 https://www.321223.com/cn/news/20160921/ 2026-11-11 01:35:45 daily 0.8 https://www.321223.com/cn/news/20160125/ 2026-11-11 01:35:25 daily 0.8 https://www.321223.com/cn/news/ 2026-11-11 01:34:45 daily 0.8 https://www.321223.com/cn/investors/listing-documents/ 2026-11-11 01:34:05 daily 0.8 https://www.321223.com/cn/investors/ir-contact/ 2026-11-11 01:33:25 daily 0.8 https://www.321223.com/cn/investors/financial-reports/ 2026-11-11 01:32:45 daily 0.8 https://www.321223.com/cn/investors/corporate-governance/ 2026-11-11 01:32:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=6 2026-11-11 01:31:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=5 2026-11-11 01:31:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=4 2026-11-11 01:31:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=3 2026-11-11 01:30:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=2 2026-11-11 01:30:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=1 2026-11-11 01:30:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/ 2026-11-11 01:29:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/通用型car-t产品ct0596及ct1190b的积极临床数据/ 2026-11-11 01:28:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/ͨ����car-t��Ʒct0596��ct1190b�Ļ����ٴ�����/ 2026-11-11 01:28:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=6 2026-11-11 01:28:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=5 2026-11-11 01:27:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=4 2026-11-11 01:27:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=3 2026-11-11 01:27:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=2 2026-11-11 01:26:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=1 2026-11-11 01:26:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=6 2026-11-11 01:26:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=5 2026-11-11 01:25:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=4 2026-11-11 01:25:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=3 2026-11-11 01:25:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=2 2026-11-11 01:24:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=1 2026-11-11 01:24:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/ 2026-11-11 01:23:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=6 2026-11-11 01:23:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=5 2026-11-11 01:23:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=4 2026-11-11 01:22:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=3 2026-11-11 01:22:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=2 2026-11-11 01:22:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=1 2026-11-11 01:21:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/ 2026-11-11 01:21:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=6 2026-11-11 01:20:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=5 2026-11-11 01:20:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=4 2026-11-11 01:20:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=3 2026-11-11 01:19:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=2 2026-11-11 01:19:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=1 2026-11-11 01:19:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/ 2026-11-11 01:18:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=6 2026-11-11 01:18:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=5 2026-11-11 01:17:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=4 2026-11-11 01:17:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=3 2026-11-11 01:17:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=2 2026-11-11 01:16:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=1 2026-11-11 01:16:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/ 2026-11-11 01:15:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=6 2026-11-11 01:15:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=5 2026-11-11 01:15:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=4 2026-11-11 01:14:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=3 2026-11-11 01:14:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=2 2026-11-11 01:14:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=1 2026-11-11 01:13:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/ 2026-11-11 01:13:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=6 2026-11-11 01:12:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=5 2026-11-11 01:12:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=4 2026-11-11 01:12:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=3 2026-11-11 01:11:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=2 2026-11-11 01:11:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=1 2026-11-11 01:11:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/ 2026-11-11 01:10:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 2026-11-11 01:10:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-11 01:09:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-11 01:09:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-11 01:09:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-11 01:08:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-11 01:08:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-11 01:07:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=5 2026-11-11 01:07:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=4 2026-11-11 01:07:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=3 2026-11-11 01:06:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=2 2026-11-11 01:06:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=1 2026-11-11 01:06:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/ 2026-11-11 01:05:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=6 2026-11-11 01:05:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=5 2026-11-11 01:04:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=4 2026-11-11 01:04:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=3 2026-11-11 01:04:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=2 2026-11-11 01:03:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=1 2026-11-11 01:03:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/ 2026-11-11 01:02:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-asco-claudin18-2-specific-car-t-cells-satri-cel-versus-treatment-of-physician-s-choice-tpc-for-previously-treated-advanced-gastric-or-gastroesophageal-junction-cancer-g-gejc-primary-results-from-a-randomized-open-label-phase-ii-trial-c/ 2026-11-11 01:02:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=5 2026-11-11 01:01:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=4 2026-11-11 01:01:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=3 2026-11-11 01:01:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=2 2026-11-11 01:00:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=1 2026-11-11 01:00:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/ 2026-11-11 00:59:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 2026-11-11 00:59:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-11 00:59:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-11 00:58:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-11 00:58:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-11 00:58:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-11 00:57:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-11 00:57:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=6 2026-11-11 00:56:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=5 2026-11-11 00:56:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=4 2026-11-11 00:56:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=3 2026-11-11 00:55:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=2 2026-11-11 00:55:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=1 2026-11-11 00:55:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/ 2026-11-11 00:54:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=6 2026-11-11 00:54:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=5 2026-11-11 00:53:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=4 2026-11-11 00:53:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=3 2026-11-11 00:53:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=2 2026-11-11 00:52:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=1 2026-11-11 00:52:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/ 2026-11-11 00:51:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=6 2026-11-11 00:51:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=5 2026-11-11 00:51:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=4 2026-11-11 00:50:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=3 2026-11-11 00:50:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=2 2026-11-11 00:50:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=1 2026-11-11 00:49:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/ 2026-11-11 00:49:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=5 2026-11-11 00:48:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=4 2026-11-11 00:48:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=3 2026-11-11 00:48:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=2 2026-11-11 00:47:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=1 2026-11-11 00:47:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/ 2026-11-11 00:46:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=6 2026-11-11 00:46:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=5 2026-11-11 00:46:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=4 2026-11-11 00:45:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=3 2026-11-11 00:45:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=2 2026-11-11 00:45:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=1 2026-11-11 00:44:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/ 2026-11-11 00:44:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=5 2026-11-11 00:43:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=4 2026-11-11 00:43:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=3 2026-11-11 00:43:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=2 2026-11-11 00:42:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=1 2026-11-11 00:42:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/ 2026-11-11 00:41:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=6 2026-11-11 00:41:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=5 2026-11-11 00:41:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=4 2026-11-11 00:40:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=3 2026-11-11 00:40:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=2 2026-11-11 00:40:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=1 2026-11-11 00:39:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/ 2026-11-11 00:39:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-gi-a-multicenter-phase-1-study-of-ab011-a-recombinant-humanized-anti-cldn18-2-monoclonal-antibody-ab011-as-monotherapy-and-combined-with-capecitabine-and-oxaliplatin-capox-in-patients-with-advanced-solid-tumors/ 2026-11-11 00:38:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=6 2026-11-11 00:38:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=5 2026-11-11 00:37:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=4 2026-11-11 00:37:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=3 2026-11-11 00:37:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=2 2026-11-11 00:36:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=1 2026-11-11 00:36:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/ 2026-11-11 00:35:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=6 2026-11-11 00:35:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=5 2026-11-11 00:35:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=4 2026-11-11 00:34:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=3 2026-11-11 00:34:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=2 2026-11-11 00:34:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=1 2026-11-11 00:33:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/ 2026-11-11 00:33:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=6 2026-11-11 00:32:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=5 2026-11-11 00:32:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=4 2026-11-11 00:32:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=3 2026-11-11 00:31:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=2 2026-11-11 00:31:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=1 2026-11-11 00:31:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/ 2026-11-11 00:30:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=6 2026-11-11 00:30:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=5 2026-11-11 00:29:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=4 2026-11-11 00:29:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=3 2026-11-11 00:29:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=2 2026-11-11 00:28:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=1 2026-11-11 00:28:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/ 2026-11-11 00:27:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-11 00:27:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-11 00:27:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-11 00:26:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-11 00:26:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-11 00:26:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-11 00:25:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=5 2026-11-11 00:25:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=4 2026-11-11 00:24:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=3 2026-11-11 00:24:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=2 2026-11-11 00:24:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=1 2026-11-11 00:23:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/ 2026-11-11 00:23:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=5 2026-11-11 00:22:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=4 2026-11-11 00:22:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=3 2026-11-11 00:22:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=2 2026-11-11 00:21:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=1 2026-11-11 00:21:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/ 2026-11-11 00:20:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=6 2026-11-11 00:20:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=5 2026-11-11 00:20:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=4 2026-11-11 00:19:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=3 2026-11-11 00:19:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=2 2026-11-11 00:19:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=1 2026-11-11 00:18:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/ 2026-11-11 00:18:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=5 2026-11-11 00:17:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=4 2026-11-11 00:17:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=3 2026-11-11 00:17:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=2 2026-11-11 00:16:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=1 2026-11-11 00:16:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/ 2026-11-11 00:15:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=5 2026-11-11 00:15:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=4 2026-11-11 00:15:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=3 2026-11-11 00:14:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=2 2026-11-11 00:14:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=1 2026-11-11 00:14:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/ 2026-11-11 00:13:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=6 2026-11-11 00:13:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=5 2026-11-11 00:12:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=4 2026-11-11 00:12:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=3 2026-11-11 00:12:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=2 2026-11-11 00:11:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=1 2026-11-11 00:11:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/ 2026-11-11 00:10:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=6 2026-11-11 00:10:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=5 2026-11-11 00:10:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=4 2026-11-11 00:09:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=3 2026-11-11 00:09:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=2 2026-11-11 00:09:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=1 2026-11-11 00:08:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/ 2026-11-11 00:08:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=6 2026-11-11 00:07:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=5 2026-11-11 00:07:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=4 2026-11-11 00:07:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=3 2026-11-11 00:06:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=2 2026-11-11 00:06:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=1 2026-11-11 00:06:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/ 2026-11-11 00:05:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=5 2026-11-11 00:05:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=4 2026-11-11 00:04:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=3 2026-11-11 00:04:25 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=2 2026-11-11 00:04:05 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=1 2026-11-11 00:03:45 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/ 2026-11-11 00:03:05 daily 0.8 https://www.321223.com/cn/investors/announcements-circulars/ 2026-11-11 00:02:25 daily 0.8 https://www.321223.com/cn/investors/ 2026-11-11 00:01:45 daily 0.8 https://www.321223.com/cn/disclaimer/ 2026-11-11 00:01:05 daily 0.8 https://www.321223.com/cn/contact-us/ 2026-11-11 00:00:25 daily 0.8 https://www.321223.com/cn/careers/join-us/ 2026-11-10 23:59:45 daily 0.8 https://www.321223.com/cn/careers/ 2026-11-10 23:59:05 daily 0.8 https://www.321223.com/cn/about-us/vision-mission-values/ 2026-11-10 23:58:25 daily 0.8 https://www.321223.com/cn/about-us/partnering/ 2026-11-10 23:57:45 daily 0.8 https://www.321223.com/cn/about-us/leadership/ 2026-11-10 23:57:05 daily 0.8 https://www.321223.com/cn/about-us/company-overview/ 2026-11-10 23:56:25 daily 0.8 https://www.321223.com/cn/about-us/ 2026-11-10 23:55:45 daily 0.8 https://www.321223.com/cn/" 2026-11-10 23:55:25 daily 0.8 https://www.321223.com/cn/ 2026-11-10 23:54:45 daily 0.8 https://www.321223.com/ 2026-11-10 23:54:25 daily 0.8 https://www.321223.com" 2026-11-10 23:54:05 daily 0.8 https://www.321223.com 2026-11-10 23:53:45 daily 0.8 http://www.321223.com<#if 2026-11-10 23:53:25 daily 0.8 http://www.321223.com/html/web/xinwenzhongxin/shipinzhuanqu/index.html 2026-11-10 23:53:05 daily 0.8 http://www.321223.com/html/web/xinwenzhongxin/fangdaxinwen/index.html 2026-11-10 23:52:45 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/index.html 2026-11-10 23:52:25 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2103055327044489218.html 2026-11-10 23:52:05 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2102682494330130434.html 2026-11-10 23:51:45 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/zhongxingshangye/index.html 2026-11-10 23:51:25 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/yihangkeji/index.html 2026-11-10 23:51:05 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/xinshengfeixiang/index.html 2026-11-10 23:50:45 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/shouhangzhishengji/index.html 2026-11-10 23:50:25 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/index.html 2026-11-10 23:50:05 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/haihangkonggu/index.html 2026-11-10 23:49:45 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/fangdategang/index.html 2026-11-10 23:49:25 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/fangdatansu/index.html 2026-11-10 23:49:05 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/dongbeizhiyao/index.html 2026-11-10 23:48:45 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/chengdutancai/index.html 2026-11-10 23:48:25 daily 0.8 http://www.321223.com/html/web/shehuizeren/zhichiguofang/index.html 2026-11-10 23:48:05 daily 0.8 http://www.321223.com/html/web/shehuizeren/yifanashui/index.html 2026-11-10 23:47:45 daily 0.8 http://www.321223.com/html/web/shehuizeren/shehuigongyi/index.html 2026-11-10 23:47:25 daily 0.8 http://www.321223.com/html/web/shehuizeren/jienenghuanbao/index.html 2026-11-10 23:47:05 daily 0.8 http://www.321223.com/html/web/shehuizeren/baozhangjiuye/index.html 2026-11-10 23:46:45 daily 0.8 http://www.321223.com/html/web/rencaifazhan/zhaopingonggao/index.html 2026-11-10 23:46:25 daily 0.8 http://www.321223.com/html/web/guanyuwomen/zuzhijiagou/index.html 2026-11-10 23:46:05 daily 0.8 http://www.321223.com/html/web/guanyuwomen/fazhanlicheng/index.html 2026-11-10 23:45:45 daily 0.8 http://www.321223.com/html/web/guanyuwomen/fangdarongyu/index.html 2026-11-10 23:45:25 daily 0.8 http://www.321223.com/html/web/guanyuwomen/fangdajianjie/index.html 2026-11-10 23:45:05 daily 0.8 http://www.321223.com/html/web/dangjianwenhua/xingfufangda/index.html 2026-11-10 23:44:45 daily 0.8 http://www.321223.com/html/web/dangjianwenhua/qiyelinian/index.html 2026-11-10 23:44:25 daily 0.8 http://www.321223.com/html/web/dangjianwenhua/dangqunhuodong/index.html 2026-11-10 23:44:05 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/yiyao/index.html 2026-11-10 23:43:45 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/index.html 2026-11-10 23:43:25 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ https:/www.cdcarbon.cn/intro/3.html 2026-11-10 23:43:05 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ https:/www.cd-ts.cn/about/7.html 2026-11-10 23:42:45 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ https:/fushuncarbon.com 2026-11-10 23:42:25 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ http:/fdtsgs.com 2026-11-10 23:42:05 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952972548200914946.html 2026-11-10 23:41:45 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952971930770006018.html 2026-11-10 23:41:25 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952969997875339266.html 2026-11-10 23:41:05 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952966690133958658.html 2026-11-10 23:40:45 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/shangye/index.html 2026-11-10 23:40:25 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/hangkong/index.html 2026-11-10 23:40:05 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/index.html 2026-11-10 23:39:45 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ https:/www.jxfangda-steels.com/index/about/id/1.html 2026-11-10 23:39:25 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ https:/www.fddzsteel.com/dg_gywm/dg_qyjj/cindex1.html 2026-11-10 23:39:05 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ http:/www.scdesheng.com/ 2026-11-10 23:38:45 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ http:/www.nhi.com.cn/html/web/guanyuwomen/gongsijianjie/index.html 2026-11-10 23:38:25 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ http:/www.fangda-specialsteels.com/web/index.aspx 2026-11-10 23:38:05 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/2062069973823197186.html 2026-11-10 23:37:45 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952982209025204225.html 2026-11-10 23:37:25 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952981773291544577.html 2026-11-10 23:37:05 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952981140610146305.html 2026-11-10 23:36:45 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952980763097620482.html 2026-11-10 23:36:25 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952980411455561730.html 2026-11-10 23:36:05 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952980023696351234.html 2026-11-10 23:35:45 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952978003895705602.html 2026-11-10 23:35:25 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952977484364046338.html 2026-11-10 23:35:05 daily 0.8 http://www.321223.com/column/95/ 2026-11-10 23:34:45 daily 0.8 http://www.321223.com/column/94/ 2026-11-10 23:34:25 daily 0.8 http://www.321223.com/column/92/ 2026-11-10 23:34:05 daily 0.8 http://www.321223.com/column/138/ 2026-11-10 23:33:45 daily 0.8 http://www.321223.com/ 2026-11-10 23:33:25 daily 0.8 http://www.321223.com https://www.yzr.com.cn/micro/main/aboutus/63ca0a89b5240a7602621d60 2026-11-10 23:33:05 daily 0.8 http://www.321223.com https://www.ykfdyy.com/ 2026-11-10 23:32:45 daily 0.8 http://www.321223.com https://www.westair.cn/stcontent/menupage/f9515923-5f75-4801-a3f3-daf09cdbb133/fd170793-0f42-499e-b03a-bc0632fe0cc5/9f991f7f-89e1-4c22-b1c7-411156b46ef0 2026-11-10 23:32:25 daily 0.8 http://www.321223.com https://www.urumqi-air.com/micro/main/aboutus/641159f50c682c7801e5a149 2026-11-10 23:32:05 daily 0.8 http://www.321223.com https://www.tjys.com.cn/html/web/guanyuyihang/gongsijianjie/index.html 2026-11-10 23:31:45 daily 0.8 http://www.321223.com https://www.tianjin-air.com/stcontent/menupage/0bbd75f1-bc38-41c6-95f4-4e3644aa70b8/7c0ff667-57c6-4de5-8e7f-e9fa5b0d4ccb/766eab66-6b64-48f7-b6de-b2ab8c2e8742 2026-11-10 23:31:25 daily 0.8 http://www.321223.com https://www.nepharm.com.cn/html/web/liaojiewomen/gongsijianjie/index.html 2026-11-10 23:31:05 daily 0.8 http://www.321223.com https://www.luckyair.net/micro/main/aboutus/641d4bbf230c607e69a9a99f 2026-11-10 23:30:45 daily 0.8 http://www.321223.com https://www.jdair.net/micro/main/article/64599c7160a9be4d4434c960 2026-11-10 23:30:25 daily 0.8 http://www.321223.com https://www.hnasatc.edu.cn/xxgk/xxjj.htm 2026-11-10 23:30:05 daily 0.8 http://www.321223.com https://www.hnair.com/guanyuhaihang/hhgs/gsjj/ 2026-11-10 23:29:45 daily 0.8 http://www.321223.com https://www.hnacargo.com/Portal2/AboutUs.aspx 2026-11-10 23:29:25 daily 0.8 http://www.321223.com https://www.gxairlines.com/stdair/tcms?directoryName=foot&fileName=CompanyAndOverview 2026-11-10 23:29:05 daily 0.8 http://www.321223.com https://www.fuzhou-air.cn/micro/main/aboutus/63db6994257effa4641ba390 2026-11-10 23:28:45 daily 0.8 http://www.321223.com https://www.fd-yy.com/html/web/guanyuwomen/yiyuanjianjie/index.html 2026-11-10 23:28:25 daily 0.8 http://www.321223.com https://www.deerjet.com/about/advantage.html 2026-11-10 23:28:05 daily 0.8 http://www.321223.com https://www.airchangan.com/content/c2aafb9c-c9a1-414e-8182-000a082ff315 2026-11-10 23:27:45 daily 0.8 http://www.321223.com http://www.zxbusiness.com/web/gyzx?nid=1 2026-11-10 23:27:25 daily 0.8 http://www.321223.com http://www.hnatechnic.com/html/web/aboutus/gongsijianjie/index.html 2026-11-10 23:27:05 daily 0.8 http://www.321223.com http://www.3-hospital-cqmu.com 2026-11-10 23:26:45 daily 0.8 http://www.321223.com /html/web/chengyuandanwei/hangkong/1953010391426195457.html 2026-11-10 23:26:25 daily 0.8 http://www.321223.com /html/web/chengyuandanwei/hangkong/1953007446785712129.html 2026-11-10 23:26:05 daily 0.8 http://www.321223.com 2026-11-10 23:25:45 daily 0.8 https://0vl1map2.321223.com 2026-11-10 23:01:33 daily 0.8